Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Outcomes-based payment

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

Xencor’s Novartis-partnered bispecific on hold after patient deaths

The two death’s included one case of CRS

- PMLiVE

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round

Cell and gene therapy

Tackling the manufacturing cost and complexity challenges

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Nerve centre gives Novartis edge in clinical trials

Algorithms predict potential delays

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links